Literature DB >> 9021573

Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.

T Kuroda1, M Saeki, M Nakano, S Mizutani.   

Abstract

The highly sensitive method to detect neuroblastoma (NB) cells using reverse transcriptase polymerase chain reaction (RT-PCR) was applied in the practical clinics, and its efficacy was assessed in the present study. Human tyrosine hydroxylase (TH), a rate-limiting enzyme in the catecholamine biosynthesis, was used as the marker for NB cells, and the expression of THmRNA was examined in 13 samples (four peripheral blood and nine bone marrow) harvested from seven patients (four with stage IV, one with stage III, two with stage II) using RT-PCR with our original primers. The positive signals for NB cells were detected in four samples (one peripheral blood and three bone marrow) by the PCR method, but were undetectable by the conventional histological examinations. In the present series, a case that showed a positive signal for NB cells in the peripheral blood showed a remarkably unfavorable clinical course, indicating that the circulating NB cells detected by the PCR method can be a sign of the progressively advanced NB, and may define a new prognostic factor suggesting higher risk. In another case, the PCR detection for the residual NB cells in the bone marrow provided important supporting evidence to determine the necessity of the additional chemotherapy and the suitable timing for bone marrow transplantation. This detection also guaranteed the safety of the bone marrow for transplantation. The PCR method was considered to be very beneficial in the selected cases. However, some problems such as the false-negative results in the negative urinary vanillylmandelic acid secretor were also highlighted in the present study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021573     DOI: 10.1016/s0022-3468(97)90097-x

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

Review 1.  Micrometastases in neuroblastoma: are they clinically important?

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

2.  Tumor cell dynamics and metastasis in advanced neuroblastoma.

Authors:  Tatsuo Kuroda; Toshiro Honna; Nobuyuki Morikawa; Yoshihiro Kitano; Yasushi Fuchimoto; Kan Terawaki; Masaaki Kumagai; Yukiko Tsunematsu; Hidekazu Masaki; Kentaro Matsuoka; Morihiro Saeki
Journal:  Pediatr Surg Int       Date:  2005-11       Impact factor: 1.827

Review 3.  Cellular kinetics of neuroblastoma and the role of surgery.

Authors:  Tatsuo Kuroda
Journal:  Pediatr Surg Int       Date:  2011-07-19       Impact factor: 1.827

4.  Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.

Authors:  D S Hoon; C T Kuo; S Wen; H Wang; L Metelitsa; C P Reynolds; R C Seeger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  Improved methods using the reverse transcriptase polymerase chain reaction to detect tumour cells.

Authors:  S A Burchill; I J Lewis; P Selby
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 6.  Opportunities and challenges of circulating biomarkers in neuroblastoma.

Authors:  Ricky M Trigg; Jacqui A Shaw; Suzanne D Turner
Journal:  Open Biol       Date:  2019-05-31       Impact factor: 6.411

7.  Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse.

Authors:  Amos H P Loh; Clara Angelina; Meng Kang Wong; Sheng Hui Tan; Sarvesh A Sukhatme; Trifanny Yeo; Su Bin Lim; York Tien Lee; Shui Yen Soh; Wing Leung; Kenneth T E Chang; Yong Wei Chua; Syed M F Alkaff; Tony K H Lim; Chwee Teck Lim; Zhi Xiong Chen
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

8.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

9.  Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.

Authors:  Na Hee Lee; Meong Hi Son; Young Bae Choi; Eunsang Yi; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo
Journal:  Cancer Res Treat       Date:  2016-03-24       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.